Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 1 (2018)

Changes in lipid metabolism in osteoarthritis patients with arterial hypertension, obesity and type 2 diabetes mellitus depending on matrilin-3 (RS77245812) and interleukin-10 (RS1800872) genes polymorphism

Author(s):
Larysa Sydorchuk, Yulia Serdulets, Andrii Sydorchuk, Olexandr Fediv and Larysa Havrysh
Abstract:
The changes of lipid metabolism were evaluated depending on genes polymorphism matrilin-3 (MATN3, rs77245812) and interleukin-10 (IL-10, rs1800872) in 74 osteoarthritis patients combined with AH, abdominal obesity, type 2 diabetes mellitus and 25 practically healthy persons. The C908Tpolymorphismof MATN3 gene associate with a high density level cholesterol(HDL) decrease (F=14.97), with increasing of low density level cholesterol(LDL) concentration (F=10.54) and increasing of an atherogenic index (AI) (F=25.12) without direct dependence on gene genotypes. While the IL-10 gene (rs1800872) promoter site associates with an increased total cholesterol (TC) content (F=20.94), slightly less with Triglycerides (F=3.46), LDL (F=7.55), very low density level cholesterol(VLDL) (F=8.78) and reduced level of HDL (F=12.78), especially in the A allele carriers. Almost half of the examined patients (56.76%) had a mixed atherogenic ІІb type of dyslipidemia by D. Fredrickson and every third (27.03%) patient evidently had an endogenous type IV hyperlipidemia (hypertriglyceridemia).
Pages: 506-511  |  978 Views  20 Downloads
How to cite this article:
Larysa Sydorchuk, Yulia Serdulets, Andrii Sydorchuk, Olexandr Fediv, Larysa Havrysh. Changes in lipid metabolism in osteoarthritis patients with arterial hypertension, obesity and type 2 diabetes mellitus depending on matrilin-3 (RS77245812) and interleukin-10 (RS1800872) genes polymorphism. Pharma Innovation 2018;7(1):506-511.
The Pharma Innovation Journal